Three Seasons Wealth LLC Raises Stock Position in Bristol Myers Squibb Company $BMY

Three Seasons Wealth LLC boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 63.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,187 shares of the biopharmaceutical company’s stock after buying an additional 14,778 shares during the quarter. Three Seasons Wealth LLC’s holdings in Bristol Myers Squibb were worth $2,200,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Davis Asset Management L.P. acquired a new position in Bristol Myers Squibb during the second quarter worth $27,000. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter worth $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $25,000. Addison Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter worth $32,000. Finally, Bayban acquired a new position in shares of Bristol Myers Squibb during the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BMY. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a report on Wednesday, August 5th. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Guggenheim reissued a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 5th. Finally, UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a Phase 2 trial evaluating a therapy in depression, expanding its pipeline into a large potential market. Positive clinical progress could provide a new growth opportunity if the treatment demonstrates efficacy and safety. Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, roughly 3.7% forward dividend yield, strong margins and growth products that are offsetting declines in older medicines. These factors support the stock’s defensive and income-oriented appeal. Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
• Neutral Sentiment: Technical indicators have reportedly turned bullish, while RBC Capital maintained a Hold rating, indicating that analysts see some upside but remain cautious about the company’s outlook. Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
• Negative Sentiment: Bristol Myers Squibb paused enrollment in its zola-cel autoimmune cell-therapy trials after safety surveillance identified inflammatory side effects. Reports that the pause involved serious safety concerns raised questions about the program’s risk profile, development timeline and broader cell-therapy strategy. What Does Bristol Myers Squibb Trial Pause Mean For Its Pipeline?
• Negative Sentiment: The wider healthcare sector traded lower, adding industry-level pressure to BMY. Investors also continue to monitor legacy-drug declines, including Opdivo, and future Eliquis patent-expiry risks. Sector Update: Healthcare Stocks Decline Friday Afternoon

Bristol Myers Squibb Stock Down 1.8%

BMY opened at $66.85 on Friday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The business has a 50 day moving average price of $62.92 and a two-hundred day moving average price of $59.92. The company has a market cap of $136.56 billion, a PE ratio of 14.72, a P/E/G ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.